Literature DB >> 6788853

Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 11 indium-oxine.

R H Wiltrout, D Taramelli, H T Holden.   

Abstract

This report describes the utilization of 111 indium-oxine chelate ([111In]Ox) for studies of macrophage-mediated cytotoxicity. [111In]Ox efficiently labeled both non-adherent and adherent tumor targets with no decrease in cell viability. Spontaneous release of intracellularly incorporated [111In]Ox was very slow (0.25-0.50%/h) from most targets, making isotope-release assays of at least 48 h feasible. In addition, released [111In]Ox was not reutilized. In contrast to its low spontaneous release from intact cells, incorporated [111In]Ox was rapidly released from tumor targets after interaction with activated macrophages. Levels of [111In]Ox released in response to cytolytic macrophages correlated well with those observed for the 51Cr and [3H]TdR radiolabels. Therefore, [111In]Ox can be utilized for relatively short-term (less than 20h) assays with lymphoma targets, as well as for longer-term assays with adherent cells. This should facilitate the testing, with the same radioisotope-release assay, of a wide range of tumor targets for susceptibility to macrophage-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6788853     DOI: 10.1016/0022-1759(81)90180-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Inhibition of pluripotent hematopoietic stem cells of bone marrow by large granular lymphocytes.

Authors:  T Barlozzari; R B Herberman; C W Reynolds
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.

Authors:  L M Weiner; G R Hudes; J Kitson; J Walczak; P Watts; S Litwin; P J O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

3.  Modulation of formation of tumor metastases by peritoneal macrophages elicited by various agents.

Authors:  E Gorelik; R H Wiltrout; D Copeland; R B Herberman
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice.

Authors:  U P Thorgeirsson; T Turpeenniemi-Hujanen; J E Williams; E H Westin; C A Heilman; J E Talmadge; L A Liotta
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

5.  Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2.

Authors:  S R Zhang; R R Salup; P E Urias; T A Twilley; J E Talmadge; R B Herberman; R H Wiltrout
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels.

Authors:  R H Wiltrout; E Gorelik; M J Brunda; H T Holden; R B Herberman
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon.

Authors:  E S Kleinerman; R H Wiltrout; R Zicht; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.

Authors:  A Celada; P W Gray; E Rinderknecht; R D Schreiber
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

9.  Leukemic cell lysis by activated human macrophages: significance of membrane-associated tumor necrosis factor.

Authors:  Y Nakabo; N Harakawa; K Yamamoto; M Okuma; K Uno; M Sasada
Journal:  Jpn J Cancer Res       Date:  1993-11

10.  Lysis of human leukemic cells by monocyte-derived macrophages activated with interferon-gamma and interleukin-2.

Authors:  T Kakita; M Sasada; T Moriguchi; T Nishimura; K Yamamoto; H Uchino
Journal:  Jpn J Cancer Res       Date:  1989-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.